



Herantis Pharma plc

Regenerative medicine for unmet clinical needs

Nordic American Life Sciences Conference, New York City 1 Dec 2016
Pekka Simula, CEO

Disclaimer

- This presentation does not intend to provide a thorough and detailed view of Herantis Pharma Plc ('Company'). The information provided in this presentation shall not be considered sufficient for making any investment decisions related to the Company. Anyone considering an investment in the Company shall read and consider carefully all information provided in the formal prospectus approved by Finland's Financial Supervisory Authority (Finanssivalvonta).
- This presentation may include forward-looking statements, estimates, and calculations related e.g. to the Company and its markets. Such forward-looking statements, estimates, and calculations are based on expectations and assumptions of the Company, which may be inaccurate or untrue. They also involve known and unknown risks and other factors, which might cause any estimates made by the Company to materially deviate from those actualized, including the operations, financial situation, and achievements of the Company. The Company cannot be held liable for any such deviations or for any actions taken by any party based on this presentation. Known risks related to the future of the Company and its business have been described in the formal prospectus approved by Finland's Financial Supervisory Authority (Finanssivalvonta).

Herantis Pharma Plc

- Drug development company based on leading science
- Focus in regenerative medicine, developing growth factor based therapies in indications with significant unmet clinical needs, aiming at disease modification:
 - Lymfactin® for Secondary Lymphedema: Phase 1-2 ongoing
 - CDF for Parkinson's disease: Phase 1-2 launching 1H/2017
 - CDF for ALS: Orphan designation granted in both USA and Europe
- IPO in Finland June 2014 raised approximately 20 MUSD

HRTIS
Nasdaq First North
Listed

HERANTIS
PHARMA


Lymfactivin® for treatment of lymphedema



- Lymphedema is a chronic, progressive swelling of the affected tissues caused by dysfunction of the lymphatic vasculature
- There is no cure or satisfactory treatment
- Lymfactivin® is a potential cure invented by professor Kari Alitalo, globally leading scientist in the field of VEGFs



Lymfactin® could cure secondary lymphedema – a growing need




HERANTIS
PHARMA

CDNF: Addressing the significant unmet needs in Parkinson's disease

- Parkinson's is a neurodegenerative disease affecting 7 million people
- Known treatments only alleviate motor symptoms
- Two huge unmet clinical needs:
Disease modification, and non-motor symptoms



CDNF* functions via several mechanisms relevant to Parkinson's disease modification



*CDNF was first published in Nature by Herantis co-founder professor Mart Saarma

Herantis is currently securing €6 million grant for its Parkinson's study



- Herantis is finalizing an EU grant agreement for €6 million for its Phase 1-2, randomised, placebo controlled clinical study in Parkinson's disease, thanks to strong scientific data
- Herantis **retains full commercial rights** to CDNF
- EU project consortium includes strong international expertise in Parkinson's: Lund and Karolinska University Hospitals, Lundbeck, Orion Pharma, University of Oxford...
- CDNF also granted orphan designation for treatment of ALS in both Europe and USA

Tekes

Herantis' Board of directors, advisory board, and management: Looking for partners for the next stage beyond 2017



Pekka Mattila
MSc, Chairman,
CEO Desentum,
Ex-CEO Finnzymes



Aki Prihti
MSc, Board member,
Founding Partner Inveni
Capital, CEO Aplagon



Timo Veromaa
MD, PhD, Board member,
Ex-CEO Biotie Therapies



Frans Wuite
MD, MBA, Board member,
CEO Acesion Pharma,
Ex-CEO Oncos Therapeutics



James Phillips
MD, MBA, Board member,
CEO Midatech, Ex-Chairman
Prosonix



Pekka Simula
MSc, CEO, Ex-CEO Oncos
Therapeutics, Ex-director
CRF Health

Jonathan Knowles
PhD, Advisory Board Chairman
Ex-IMI Chairman, Ex-Mgmt team
Roche, Ex-Board member Chugai
Pharmaceutical and Genentech



HERANTIS

PHARMA

Thank you

Herantis Pharma Plc
Viikinkaari 4, FI-00790 Helsinki, Finland
www.herantis.com
info@herantis.com